Solera Health recently launched a program that aims to help patients who are interested in GLP-1s gain access to lifestyle change support. It also provides educational materials on GLP-1s.

If we want to support people with obesity, the weight loss debate must stop conflating obesity prevention with obesity treatment. Instead, we should focus on the tools that best solve the needs of people where they are – just as we would for cancer or diabetes – by making the most effective treatments possible available.

Novo Nordisk weight-loss drug Wegovy reduced the risk of major cardiovascular events by 20% in a large clinical trial. The company said the results support expanding the drug’s label, but the looming question is whether the data will persuade payers to cover the pricey chronic therapy.

Hello Alpha launched Ahead with Alpha, a weight management program for employers. It offers access to primary care providers trained in obesity care, medication management through weight loss drugs like GLP-1s, nutrition counseling with a registered dietitian and progress tracking. 

Alfie Health’s $2.1 million seed funding was led by Y Combinator and Nina Capital. It included participation from Goodwater Capital, Phoenix Investment Club and several angel investors.

Through LifeMD’s new weight management program, consumers can gain access to GLP-1 prescriptions like Ozempic and Wegovy, clinical support, lab testing, education and more.